State of Wisconsin Investment Board lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,294 shares of the biopharmaceutical company’s stock after buying an additional 1,282 shares during the quarter. State of Wisconsin Investment Board’s holdings in Alnylam Pharmaceuticals were worth $1,914,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Kornitzer Capital Management Inc. KS bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $19,131,000. Tocqueville Asset Management L.P. boosted its stake in Alnylam Pharmaceuticals by 25.3% in the third quarter. Tocqueville Asset Management L.P. now owns 20,775 shares of the biopharmaceutical company’s stock valued at $2,441,000 after buying an additional 4,200 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at about $349,000. Fayerweather Charles acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at about $230,000. Finally, Aperio Group LLC boosted its stake in Alnylam Pharmaceuticals by 5.1% in the third quarter. Aperio Group LLC now owns 16,908 shares of the biopharmaceutical company’s stock valued at $1,987,000 after buying an additional 823 shares in the last quarter. 86.04% of the stock is owned by institutional investors and hedge funds.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the sale, the president now directly owns 165,399 shares in the company, valued at $16,539,900. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Barry E. Greene sold 85,316 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total value of $10,664,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 289,797 shares of company stock valued at $34,422,712. 4.30% of the stock is currently owned by corporate insiders.

ALNY has been the topic of several research analyst reports. Credit Suisse Group raised their price objective on Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 price objective (down from $98.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 7th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $14.71 price objective (down from $188.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 2nd. B. Riley started coverage on Alnylam Pharmaceuticals in a research note on Wednesday, November 1st. They issued a “buy” rating and a $240.00 price objective on the stock. Finally, Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, September 11th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have given a buy rating to the stock. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $121.85.

Alnylam Pharmaceuticals, Inc. (ALNY) opened at $132.33 on Thursday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $35.98 and a 1 year high of $147.63. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The business had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The company’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.21) earnings per share. equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -5.33 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/alnylam-pharmaceuticals-inc-alny-shares-bought-by-state-of-wisconsin-investment-board/1721370.html.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.